Core Viewpoint - Cue Biopharma, Inc. is initiating an underwritten public offering of its common stock and accompanying warrants, subject to market conditions and uncertainties regarding the offering's completion and terms [1] Group 1: Offering Details - The public offering includes shares of common stock or pre-funded warrants to purchase common stock, along with accompanying warrants [1] - Oppenheimer & Co. is the sole book-running manager, while Newbridge Securities Corporation is acting as co-manager for the offering [2] - A shelf registration statement related to the offering was filed with the SEC on May 9, 2023, and declared effective on May 26, 2023 [3] Group 2: Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics that selectively engage and modulate disease-specific T cells [5] - The company's proprietary platform, Immuno-STAT™, aims to harness the immune system's potential without broad systemic immune modulation [5] - The company is headquartered in Boston, Massachusetts, and is led by a management team with expertise in immunology and immuno-oncology [6]
Cue Biopharma Announces Proposed Public Offering